We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Common Variant Modifiers for Syndromic Heart Condition Located

By LabMedica International staff writers
Posted on 09 Jan 2020
DiGeorge syndrome, also known as 22q11. More...
2 deletion syndrome, is a syndrome caused by the deletion of a small segment of chromosome 22. While the symptoms can vary, they often include congenital heart problems, specific facial features, frequent infections, developmental delay, learning problems and cleft palate.

DiGeorge syndrome is typically due to the deletion of 30 to 40 genes in the middle of chromosome 22 at a location known as 22q11.2. About 90% of cases occur due to a new mutation during early development, while 10% are inherited from a person's parents. It is autosomal dominant, meaning that only one affected chromosome is needed for the condition to occur. Diagnosis is suspected based on the symptoms and confirmed by genetic testing.

A large team of scientists working with those at the Albert Einstein College of Medicine (Bronx, NY, USA) searched for rare disease modifiers using whole-genome sequence data for more than 1,000 individuals with 22q11.2 deletion syndrome (22q11.2DS), before doing common variant searches with case-control data and genome-wide association meta-analyses. Together, their analyses led to a block of common variants in and around CRKL, including a single nucleotide polymorphism (SNP) influencing the expression of that enzyme-coding proto-oncogene. While the individuals all had 22q11.2DS, more than 40% had conotruncal heart defects and almost 56% had any type of congenital heart diagnosis, while 469 individuals were not affected by heart disease or other conditions considered.

Bernice E. Morrow, a professor of Genetics and senior author of the study, said, “Complete sequence data indicate that this association was not driven by rare variants individually or jointly in the same region, suggesting that associated common variants are among the top causal variants.”

The author concluded that their findings suggest that variance in conotruncal type defects (CTD) penetrance in the 22q11.2DS population can be explained in part by variants affecting CRKL expression. Haploinsufficiency of this region alone is associated with conotruncal defects, and when taken together with mouse genetic studies, the results presented implicate, most plausibly, CRKL as a possible target of non-coding putative regulatory variants. The study was published on December 20, 2019 in the American Journal of Human Genetics.

Related Links:
Albert Einstein College of Medicine


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.